

Pathologic findings from the National Surgical Adjuvant
prognostic significance of erbB-2 protein overexpressio

Journal of Clinical Oncology

8, 103-112

DOI: 10.1200/jco.1990.8.1.103

Citation Report

#	ARTICLE	IF	CITATIONS
1	Oncogene Amplification and Expression: Importance of Methodologic Considerations. American Journal of Clinical Pathology, 1990, 94, 240-241.	0.4	14
2	4. The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer. International Journal of Cancer, 1990, 46, 55-61.	2.3	115
3	Differentiation of cultured human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surfaceHER-2/neu antigen. Molecular Carcinogenesis, 1990, 3, 350-362.	1.3	101
4	Stimulatory and inhibitory growth factors and breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 1990, 37, 795-803.	1.2	23
5	Adjuvant systemic therapy of stage I and II breast cancer. Seminars in Oncology Nursing, 1991, 7, 175-186.	0.7	2
6	Expression of Her-2/neu oncogene protein product and epidermal growth factor receptors in surgical specimens of human breast cancers. American Journal of Surgery, 1991, 161, 580-583.	0.9	8
7	Les facteurs pronostiques biologiques dans le cancer du sein. Immuno-Analyse Et Biologie Specialisee, 1991, 6, 23-28.	0.0	0
8	Recent Advances in the Treatment of Breast Cancer. American Journal of the Medical Sciences, 1991, 301, 337-352.	0.4	3
9	c-erbB-2 oncogene as a prognostic marker in breast cancer. British Journal of Cancer, 1991, 63, 328-332.	2.9	146
10	Quantification of levels in tissue. Methods in Enzymology, 1991, 198, 290-300.	0.4	10
11	c-erbB-2 oncoprotein expression in primary and advanced breast cancer. British Journal of Cancer, 1991, 63, 439-443.	2.9	228
12	Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. Annals of Oncology, 1991, 2, 47-53.	0.6	38
13	Medical management of early-stage breast cancer. Current Problems in Cancer, 1991, 15, 161-232.	1.0	1
14	Diagnostic utility of oncogenes and their products in human cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 1991, 1072, 193-214.	3.3	12
15	Prognostic significance of her-2/neu expression in breast cancer and its relationship to other prognostic factors. International Journal of Cancer, 1991, 49, 44-49.	2.3	250
16	Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro and in nude mice. International Journal of Cancer, 1991, 49, 616-623.	2.3	52
17	Association of C-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. International Journal of Cancer, 1991, 49, 650-655.	2.3	352
18	C-ERBB-2 oncogenes protein in situ and invasive lobular breast neoplasia. Cancer, 1991, 68, 331-334.	2.0	85

#	ARTICLE	IF	CITATIONS
19	DNA flow cytometric analysis of primary operable breast cancer. Relation of ploidy and S-Phase fraction to outcome of patients in NSABP B-04. <i>Cancer</i> , 1991, 68, 1465-1475.	2.0	102
20	Should all patients with node-negative breast cancer receive adjuvant therapy? Identifying additional subsets of low-risk patients who are highly curable by surgery alone. <i>Cancer</i> , 1991, 68, 1482-1494.	2.0	42
21	DNA content flow cytometry as a prognostic factor for node-positive breast cancer. The role of multiparameter ploidy analysis and specimen sonication. <i>Cancer</i> , 1991, 68, 1781-1788.	2.0	30
22	Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 1991, 20, 3-10.	1.1	21
23	Response to treatment of breast cancer. <i>Breast Cancer Research and Treatment</i> , 1991, 18, S147-S155.	1.1	4
24	Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic. <i>Journal of Clinical Immunology</i> , 1991, 11, 117-127.	2.0	278
25	c-erbB-2 expression in different histological types of invasive breast carcinoma.. <i>Journal of Clinical Pathology</i> , 1991, 44, 211-214.	1.0	66
26	HER2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies.. <i>Journal of Clinical Pathology</i> , 1992, 45, 726-727.	1.0	22
27	Prognostic value of c-erbB-2 expression in uterine cervical carcinoma.. <i>Journal of Clinical Pathology</i> , 1992, 45, 594-596.	1.0	53
29	Molecular Biology in the Diagnosis and Prognosis of Solid and Lymphoid Tumors. <i>Cancer Investigation</i> , 1992, 10, 399-416.	0.6	6
30	The Polymerase Chain Reaction: Its use in the Molecular Characterization and Diagnosis of Cancers. <i>Cancer Investigation</i> , 1992, 10, 417-429.	0.6	8
31	ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 5321-5325.	3.3	493
32	c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis. <i>British Journal of Cancer</i> , 1992, 66, 728-734.	2.9	25
33	Antiserum raised against a synthetic phosphotyrosine-containing peptide selectively recognizes p185neu/erbB-2 and the epidermal growth factor receptor.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 11637-11641.	3.3	50
34	Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute.. <i>Journal of Clinical Oncology</i> , 1992, 10, 976-983.	0.8	306
35	Clinical Significance of erbB-2 (HER-2/neu) Protein. <i>Cancer Investigation</i> , 1992, 10, 575-579.	0.6	19
36	Applications of image cytometry in the diagnostic laboratory. <i>Clinical Immunology Newsletter</i> , 1992, 12, 41-48.	0.1	0
37	Growth factors in breast cancer: Mitogenesis to transformation. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1992, 43, 69-78.	1.2	42

#	ARTICLE	IF	CITATIONS
38	The role of axillary dissection in operable breast cancer. <i>Breast</i> , 1992, 1, 41-49.	0.9	36
39	Prognostic factors in human primary breast cancer: Comparison of c-myc and HER2/neu amplification. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1992, 43, 13-19.	1.2	44
40	Identification and interpretation of epidermal growth factor and c-erbB-2 overexpression. <i>European Journal of Cancer</i> , 1992, 28, 263-267.	1.3	35
41	Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. <i>Human Pathology</i> , 1992, 23, 1141-1150.	1.1	53
42	Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. <i>Human Pathology</i> , 1992, 23, 974-979.	1.1	376
43	HER-2/neu expression: A major prognostic factor in endometrial cancer. <i>Gynecologic Oncology</i> , 1992, 47, 179-185.	0.6	212
44	C-erbB-2-oncogene expression in breast carcinoma: Analysis by S1 nuclease protection assay and immunohistochemistry in relation to clinical parameters. <i>Gynecologic Oncology</i> , 1992, 47, 228-233.	0.6	11
45	Prognostic indicators in node-negative early stage breast cancer. <i>American Journal of Medicine</i> , 1992, 92, 539-548.	0.6	20
46	HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.. <i>Journal of Clinical Oncology</i> , 1992, 10, 599-605.	0.8	433
47	Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features.. <i>Journal of Clinical Oncology</i> , 1992, 10, 686-695.	0.8	86
48	Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients.. <i>Journal of Clinical Oncology</i> , 1992, 10, 1436-1443.	0.8	117
49	Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.. <i>Journal of Clinical Oncology</i> , 1992, 10, 1049-1056.	0.8	791
50	Oncogenes in Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 1992, 6, 813-827.	0.9	20
51	Study of the biological and prognostic significance of the antigen CaMBr8 on breast carcinoma. <i>British Journal of Cancer</i> , 1992, 65, 466-470.	2.9	5
52	Hormonal aspects of breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 1992, 12, 1-23.	2.0	128
53	Therapy of small breast cancer: A prospective study on 1036 patients with special emphasis on prognostic factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 1992, 23, 907-914.	0.4	29
54	Proliferating cell nuclear antigen in breast lesions: Correlation of c-erbB-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer. <i>Virchows Archiv A, Pathological Anatomy and Histopathology</i> , 1992, 421, 193-202.	1.4	33
55	The value of prognostic factors in selecting node-negative breast cancer patients for adjuvant therapy. <i>Journal of Surgical Oncology</i> , 1992, 49, 73-75.	0.8	1

#	ARTICLE	IF	CITATIONS
56	Prognosis and treatment decisions in patients with breast cancer without axillary node involvement. <i>Cancer</i> , 1992, 70, 1775-1781.	2.0	30
57	Steroid hormone receptor immunohistochemistry and amplification of c-myc protooncogene relationship to disease-free survival in breast cancer. <i>Cancer</i> , 1993, 71, 162-171.	2.0	32
58	Pathologic findings from the national surgical adjuvant breast project (protocol 4): Discriminants for 15-year survival. <i>Cancer</i> , 1993, 71, 2141-2150.	2.0	103
59	Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients. <i>Cancer</i> , 1993, 71, 2499-2506.	2.0	188
60	Serum levels of HER-2neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. <i>Cancer</i> , 1993, 71, 3942-3946.	2.0	78
61	Reduced expression of nm23-H1, but not of nm23-H2, is concordant with the frequency of lymph-node metastasis of human breast cancer. <i>International Journal of Cancer</i> , 1993, 55, 66-71.	2.3	132
62	Quest for excellence: The ultimate goal of the radiation oncologist: ASTRO gold medal address, 1992. <i>International Journal of Radiation Oncology Biology Physics</i> , 1993, 26, 567-580.	0.4	9
63	Predicting recurrence in axillary-node negative breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 1993, 25, 127-139.	1.1	49
64	The role of erbB2 signal transduction pathways in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 1993, 27, 83-93.	1.1	60
65	Detection of c-erbB-2 amplification in breast cancer by in situ hybridization. <i>Breast</i> , 1993, 2, 234-238.	0.9	7
66	Regulation of proliferation and differentiation of normal and malignant breast: new factors and neu paradoxes. <i>Breast</i> , 1993, 2, 83-86.	0.9	2
67	C-erbB-2 Oncogene Product Expression Depends on Tumour Type and is Related to Oestrogen Receptor and Lymph Node Status in Human Breast Carcinoma. <i>Pathology Research and Practice</i> , 1993, 189, 261-266.	1.0	17
68	The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. <i>American Journal of Obstetrics and Gynecology</i> , 1993, 168, 228-232.	0.7	30
69	What's New in Breast Cancer?. <i>Pathology Research and Practice</i> , 1993, 189, 1233-1252.	1.0	23
70	c-erbB-2 Amplification and overexpression in breast cancer: evaluation and comparison of southern BLOT, SLOT BLOT, ELISA and immunohistochemistry. <i>Pathology</i> , 1993, 25, 124-132.	0.3	20
71	Prognostic Factors and Therapeutic Decisions in Axillary Node-Negative Breast Cancer. <i>Annual Review of Medicine</i> , 1993, 44, 201-210.	5.0	117
72	Prognostic significance of c-erbB-2 expression in node negative breast cancer. <i>British Journal of Cancer</i> , 1993, 67, 625-629.	2.9	77
73	Prognostic significance of Helix pomatia lectin and c-erbB-2 oncoprotein in human breast cancer. <i>British Journal of Cancer</i> , 1993, 68, 621-626.	2.9	26

#	ARTICLE	IF	CITATIONS
74	Prognostic Indicators in Early Breast Cancer. American Journal of the Medical Sciences, 1993, 305, 176-182.	0.4	24
75	Expression of the c-erbB-2 (Her-2/neu) Oncoprotein in Human Prostatic Carcinoma. Journal of Urology, 1993, 150, 1427-1433.	0.2	150
76	Amplification of c-erbB-2, int-2 and c-myc Genes in Node-Negative Breast Carcinomas: Relationship to Prognosis. Acta OncolÅ³gica, 1993, 32, 289-294.	0.8	15
77	Improved Quantitation of HER-2/neuGene Copy Number in Breast Tumor-Derived DNA Samples. American Journal of Clinical Pathology, 1993, 100, 444-450.	0.4	7
79	Expression of Hormone Receptors, Cathepsin D, and HER-2/neu Oncoprotein in Normal Colon and Colonic Disease. Archives of Surgery, 1993, 128, 637.	2.3	25
80	Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.. Journal of Clinical Oncology, 1993, 11, 36-43.	0.8	110
81	Overview of the Biologic Markers of Breast Cancer. Hematology/Oncology Clinics of North America, 1994, 8, 73-100.	0.9	56
82	C-ERBB-2, RAS P21, AND C-MYC EXPRESSION IN BREAST-CARCINOMA - PROGNOSTIC VALUE AND CORRELATION WITH CLINICOPATHOLOGICAL AND BIOLOGIC VARIABLES. International Journal of Oncology, 1994, 4, 255-60.	1.4	0
83	Light and Electron Microscopic Study of an Invasive Cribriform Carcinoma with Extensive Microcalcification Developing in a Breast with Silicone Augmentation. Ultrastructural Pathology, 1994, 18, 519-523.	0.4	15
85	Is C-ERB B-2 a predictor for recurrent disease in early stage breast cancer?. International Journal of Radiation Oncology Biology Physics, 1994, 28, 395-403.	0.4	17
86	Comparison of estrogen and progesterone receptor status to lymphocyte immunity against tumor antigens in breast cancer patients. Breast Cancer Research and Treatment, 1994, 30, 299-304.	1.1	9
87	Modulation of breast cancer progression and differentiation by thegp30/neregulin. Breast Cancer Research and Treatment, 1994, 31, 175-182.	1.1	23
88	C-erbB-2 overexpression in primary breast cancer: independent prognostic factor in patients at high risk. Breast Cancer Research and Treatment, 1994, 29, 287-295.	1.1	26
89	Survival differences between black and white women with breast cancer. Journal of Surgical Oncology, 1994, 55, 37-41.	0.8	17
90	ElevatederbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer, 1994, 73, 652-658.	2.0	98
91	Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer, 1994, 73, 2359-2365.	2.0	200
92	Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer, 1994, 74, 2956-2963.	2.0	93
93	Simultaneous analysis of c-erb B-2 expression and DNA content in breast cancer using flow cytometry. Cytometry, 1994, 16, 160-168.	1.8	36

#	ARTICLE	IF	CITATIONS
94	Theory and methodology of evaluating genetic alterations. <i>Diagnostic Cytopathology</i> , 1994, 10, 289-298.	0.5	4
95	Immunocytochemical staining of c-erbB-2 oncogene in fine-needle aspirates of breast carcinoma: A comparison with tissue sections and other breast cancer prognostic factors. <i>Diagnostic Cytopathology</i> , 1994, 11, 250-254.	0.5	34
96	Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy. <i>Journal of Cancer Research and Clinical Oncology</i> , 1994, 120, 378-381.	1.2	37
97	The biology of erbB-2/neu/HER-2 and its role in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 1994, 1198, 165-184.	3.3	504
98	Salivary duct carcinoma. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1994, 78, 74-80.	0.6	93
99	erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. <i>British Journal of Cancer</i> , 1994, 70, 819-825.	2.9	87
100	c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer. <i>New England Journal of Medicine</i> , 1994, 330, 1260-1266.	13.9	927
101	Expression of neu/c-erbB-2 in human brain tumors. <i>Human Pathology</i> , 1994, 25, 772-780.	1.1	42
103	Current Management of Carcinoma of the Breast. <i>Annals of Surgery</i> , 1994, 220, 121-136.	2.1	27
104	The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. <i>British Journal of Cancer</i> , 1994, 70, 335-341.	2.9	142
105	The Family of c-erbB Genes: From Basic Research to Clinical Oncology. <i>Oncology Research and Treatment</i> , 1994, 17, 346-357.	0.8	8
106	Evaluation of c-erbB-2 Amplification in Breast Carcinoma by Differential Polymerase Chain Reaction. <i>American Journal of Clinical Pathology</i> , 1994, 101, 493-499.	0.4	25
107	Prognostic Association of C-ErbB-2 Oncogene Amplification and Protein Overexpression in Human Breast Cancer Using Archival Tissues a Comparative Study. <i>Acta Oncologica</i> , 1994, 33, 493-498.	0.8	7
108	Overexpression of p53 and HER-2/neu Proteins as Prognostic Markers in Early Stage Breast Cancer. <i>Annals of Surgery</i> , 1994, 219, 332-341.	2.1	97
109	Adjuvant Therapy of Node-Negative Breast Cancer. <i>Annals of Pharmacotherapy</i> , 1995, 29, 289-298.	0.9	2
110			

#	ARTICLE	IF	CITATIONS
113	Prognosis of breast cancer: Evidence for interaction between c-erbB-2 overexpression and number of involved axillary lymph nodes. <i>Journal of Surgical Oncology</i> , 1995, 60, 106-111.	0.8	19
114	Comparison of immunoreactivity of neu oncoprotein in fine-needle aspirates and paraffin-embedded materials. <i>Diagnostic Cytopathology</i> , 1995, 12, 142-145.	0.5	7
115	A flow cytometric study of c-erbB-3 expression in breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 1995, 41, 280-286.	2.0	5
116	The relationship between flow-cytometric and immunohistochemically detected c-erbB-2 expression, grade and DNA ploidy in breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 1995, 41, 137-145.	2.0	8
117	Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. <i>British Journal of Cancer</i> , 1995, 71, 840-844.	2.9	210
118	Are fine-needle breast aspirates representative of the underlying solid tumour? A comparison of receptor levels, ploidy and the influence of cytokeratin gates. <i>British Journal of Cancer</i> , 1995, 72, 732-737.	2.9	14
119	Prognostic value of proliferating cell nuclear antigen and c-erbB-2 compared with conventional histopathological factors in breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 1995, 121, 115-122.	1.2	11
120	Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. <i>International Journal of Gastrointestinal Cancer</i> , 1995, 17, 15-21.	0.4	66
121	Breast Cancer Genetics: Relevance to Oncology Practice. <i>Cancer Control</i> , 1995, 2, 107327489500200.	0.7	2
122	Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.. <i>Journal of Clinical Oncology</i> , 1995, 13, 1129-1135.	0.8	277
123	Immunohistochemical detection ofHER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis. <i>Cancer</i> , 1995, 75, 1320-1326.	2.0	101
124	Prediction of Recurrence for Advanced Breast Cancer. <i>Surgical Oncology Clinics of North America</i> , 1995, 4, 601-632.	0.6	14
125	COEXPRESSION OF C-ERBB2 AND INT-2 ONCOGENES IN INVASIVE BREAST-CANCER. <i>International Journal of Oncology</i> , 1995, 6, 977-84.	1.4	0
126	Growth Factors in Breast Cancer. <i>Endocrine Reviews</i> , 1995, 16, 559-589.	8.9	347
127	The use of anthracyclines in the adjuvant treatment of breast cancer. <i>Cancer Treatment Reviews</i> , 1995, 21, 199-214.	3.4	5
128	The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review. <i>Gene</i> , 1995, 159, 19-27.	1.0	234
129	EGF and Overexpression of the Oncogene c-erbB-2 in Ovarian Cancer: Immunohistochemical Findings and Prognostic Value. <i>Journal of Obstetrics and Gynaecology (Tokyo, Japan)</i> , 1995, 21, 167-178.	0.1	32
130	ADJUVANT CHEMOTHERAPY IN THE NODE-NEGATIVE BREAST CANCER PATIENT. <i>Surgical Clinics of North America</i> , 1996, 76, 327-341.	0.5	10

#	ARTICLE	IF	CITATIONS
131	DNA Ploidy, Cell Kinetics, and Epidermal Growth Factor Receptor and HER2/neu Oncoprotein Expression in Primary Operable Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 1996, 784, 472-481.	1.8	8
132	The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer. <i>European Journal of Cancer</i> , 1996, 32, 63-68.	1.3	66
133	Anti-oestrogen stimulation of ERBB2 ectodomain shedding from BT-474 human breast cancer cells with ERBB2 gene amplification. <i>European Journal of Cancer</i> , 1996, 32, 134-140.	1.3	9
134	Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 1641-1674.	2.2	450
135	c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.. <i>Journal of Clinical Oncology</i> , 1996, 14, 2702-2708.	0.8	380
136	Relationship of Haptoglobin-Related Protein (OA-519) to Newer Prognostic Markers in Breast Cancer. An Immunohistochemical Study on Routine Paraffin Sections. <i>Journal of Histotechnology</i> , 1996, 19, 13-22.	0.2	0
137	Hereditary Onset of Multiple Seborrhic Keratoses: A Variant of Leser TrÄ©lat Sign?. <i>Journal of Dermatology</i> , 1996, 23, 191-195.	0.6	6
138	Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.. <i>Journal of Clinical Oncology</i> , 1996, 14, 2843-2877.	0.8	486
139	Use of a Polyclonal Antibody for the Determination of the Prognostic Value of c-erbB-2 Protein Over-Expression in Human Breast Cancer. <i>Acta OncolÄ³gica</i> , 1996, 35, 23-30.	0.8	7
140	Fluorescence <i>in Situ</i> Hybridization for Detecting ErbB-2 Amplification in Breast Tumor Fine Needle Aspiration Biopsies. <i>Acta Cytologica</i> , 1996, 40, 164-173.	0.7	59
141	The performance of e23(Fv)PEs, recombinant toxins targeting the erbB-2 protein. <i>Seminars in Cancer Biology</i> , 1996, 7, 79-86.	4.3	16
142	Preclinical testing of an anti-erbB-2 recombinant toxin. <i>Breast Cancer Research and Treatment</i> , 1996, 38, 19-25.	1.1	16
143	The significance of heregulin in breast cancer tumor progression and drug resistance. <i>Breast Cancer Research and Treatment</i> , 1996, 38, 57-66.	1.1	106
144	Transgenic mouse models of breast cancer. <i>Breast Cancer Research and Treatment</i> , 1996, 39, 119-135.	1.1	47
145	PROGNOSTIC SIGNIFICANCE OF c-erbB-2 ONCOGENE IN AXILLARY NODE-NEGATIVE BREAST CANCER. <i>ANZ Journal of Surgery</i> , 1996, 66, 64-70.	0.3	14
146	PROGNOSTIC SIGNIFICANCE OF THE CO-EXPRESSION OF p53 AND c-erbB-2 PROTEINS IN BREAST CANCER. , 1996, 179, 31-38.		66
147	Serial serum c-erbB-2 levels in patients with breast carcinoma. , 1996, 78, 267-272.		49
148	Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: A case-control study. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996, 35, 751-757.	0.4	74

#	ARTICLE	IF	CITATIONS
149	Growth factors in lung cancer. <i>Growth Factors and Cytokines in Health and Disease</i> , 1997, , 355-380.	0.2	0
150	Expression of the invasive phenotype by MCF-7 human breast cancer cells transfected to overexpress protein kinase C-alpha or the erbB2 proto-oncogene. <i>International Journal of Oncology</i> , 1997, 10, 71.	1.4	4
151	Serum erbB-2 in Ductal Carcinoma in situ of the Breast—A Marker of Microinvasion?. <i>Acta Oncologica</i> , 1997, 36, 651-652.	0.8	1
152	Applications of genetic technologies to cancer screening, prevention, diagnosis, prognosis, and treatment. <i>Seminars in Oncology Nursing</i> , 1997, 13, 74-81.	0.7	7
153	Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. <i>Clinica Chimica Acta</i> , 1997, 262, 99-119.	0.5	38
154	HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.. <i>Journal of Clinical Oncology</i> , 1997, 15, 2894-2904.	0.8	748
155	Hormones and Cancer. , 1997, , 513-523.		1
156	Prognostic Factors in Breast Cancer. <i>Breast Journal</i> , 1997, 3, 267-283.	0.4	3
157	Protein tyrosine kinases and cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 1997, 1333, F217-F248.	3.3	138
158	Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 1997, 43, 87-95.	1.1	66
159	Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. <i>Breast Cancer Research and Treatment</i> , 1997, 42, 1-5.	1.1	86
160	Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy. <i>Breast Cancer Research and Treatment</i> , 1998, 52, 65-77.	1.1	236
161	Transformation of NIH3T3 fibroblasts by the c-Kit receptor tyrosine kinase: effect of receptor density and ligand-requirement. <i>Oncogene</i> , 1998, 16, 179-190.	2.6	26
162	Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients. , 1998, 76, 824-828.		70
163	A case of multiple juvenile papillomatosis of the breast and its immunohistochemical pathology. <i>Breast Cancer</i> , 1998, 5, 187-193.	1.3	3
165	The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. <i>Stem Cells</i> , 1998, 16, 413-428.	1.4	704
166	p34cdc2 in invasive breast cancer: relationship to DNA content, Ki67 index and c-erbB-2 expression. <i>Histopathology</i> , 1998, 33, 522-530.	1.6	13
167	Immunohistochemical analysis of the oncoprotein c-erbB-2 expression in oral benign and malignant lesions. <i>International Journal of Oral and Maxillofacial Surgery</i> , 1998, 27, 209-212.	0.7	22

#	ARTICLE	IF	CITATIONS
168	Adjacent Carboxyterminal Tyrosine Phosphorylation Events Identify Functionally Distinct ErbB2 Receptor Subsets: Implications for Molecular Diagnostics. <i>Experimental Cell Research</i> , 1998, 241, 467-475.	1.2	12
169	Genetic and epigenetic regulation of human breast cancer progression and metastasis. <i>Endocrine-Related Cancer</i> , 1998, 5, 155-197.	1.6	26
170	No evidence of significant activity of the multidrug resistance gene product in primary human breast cancer. <i>Annals of Oncology</i> , 1998, 9, 85-93.	0.6	22
171	neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.. <i>Journal of Clinical Oncology</i> , 1998, 16, 1340-1349.	0.8	402
172	Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.. <i>Journal of Clinical Oncology</i> , 1998, 16, 2409-2416.	0.8	62
173	The Prognostic Significance of c-erbB-2 Serum Protein in Metastatic Breast Cancer. <i>Oncology</i> , 1998, 55, 33-38.	0.9	54
174	The HER-2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. <i>Oncologist</i> , 1998, 3, 237-252.	1.9	297
175	C-erbB-2 Expression in Primary Breast Cancer. <i>International Journal of Biological Markers</i> , 1999, 14, 16-26.	0.7	24
176	Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry for the Evaluation of HER-2/ neu in Breast Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 1974-1974.	0.8	283
177	c-Src, Receptor Tyrosine Kinases, and Human Cancer. <i>Advances in Cancer Research</i> , 1999, 76, 61-119.	1.9	203
178	Marked Intratumoral Heterogeneity of the Proto-Oncogene Her-2/ neu Determined by Three Different Detection Systems. <i>Breast Journal</i> , 1999, 5, 369-374.	0.4	60
179	The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. <i>Seminars in Cancer Biology</i> , 1999, 9, 125-138.	4.3	156
180	Cancer Vaccines. , 1999, 81, 121-139.		31
181	Molecular Chemotherapy for Breast Cancer. <i>Drugs and Aging</i> , 1999, 14, 75-90.	1.3	26
182	Biology of high risk benign breast lesions. <i>Advances in Oncobiology</i> , 1999, 2, 81-116.	0.0	0
183	Immunohistochemical Biomarkers in Breast Cancer. <i>Journal of Histotechnology</i> , 1999, 22, 249-261.	0.2	1
184	HER2 as a Predictor of Therapeutic Response in Breast Cancer. <i>Breast Disease</i> , 2000, 11, 91-102.	0.4	22
185	Expression of erbB Receptors and their Ligands in Breast Cancer: Implications to Biological Behavior and Therapeutic Response. <i>Breast Disease</i> , 2000, 11, 63-75.	0.4	22

#	ARTICLE	IF	CITATIONS
186	HER2/neu: A Target for Breast Cancer Therapy. <i>Breast Disease</i> , 2000, 11, 7-18.	0.4	10
187	CORRELATIONSHIP OF HORMONE RECEPTOR STATUS, p53 MUTATION AND c-erb B-2 OVEREXPRESSION WITH NUCLEAR GRADING IN BREAST CANCERS. <i>Medical Journal Armed Forces India</i> , 2000, 56, 305-308.	0.3	0
188	The prognostic value of p53 and c-erb b-2 immunostaining is overrated for patients with lymph node negative breast carcinoma. , 2000, 88, 804-813.		105
189	Role of HER2 gene overexpression in breast carcinoma. <i>Journal of Cellular Physiology</i> , 2000, 182, 150-162.	2.0	258
190	Angiogenesis, p53, and c-erbB-2 immunoreactivity and clinicopathological features in male breast cancer. <i>Journal of Surgical Oncology</i> , 2000, 75, 252-257.	0.8	34
191	C-erbB-2 expression and response to treatment in metastatic breast cancer. <i>Medical Oncology</i> , 2000, 17, 22-28.	1.2	12
192	Prognostic significance of c-erb B-2 protein status using an enzyme immunoassay in breast cancer. <i>International Journal of Clinical Oncology</i> , 2000, 5, 12-17.	1.0	0
193	Assessment of Prognostic Factors in Breast Fine-Needle Aspirates. <i>Pathology Patterns Reviews</i> , 2000, 113, S84-S96.	0.4	9
194	Overexpression of Her-2 in Patients With Poorly Differentiated Carcinoma or Poorly Differentiated Adenocarcinoma of Unknown Primary Site. <i>Journal of Clinical Oncology</i> , 2000, 18, 632-632.	0.8	68
196	HER-2/neu Protein Expression in Breast Cancer Evaluated by Immunohistochemistry. <i>American Journal of Clinical Pathology</i> , 2000, 113, 251-258.	0.4	99
197	Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines.. <i>International Journal of Oncology</i> , 2000, 17, 629-41.	1.4	33
198	HER-2/ neuOncogene Amplification Determined by Fluorescence In Situ Hybridization. , 2001, 49, 93-104.		3
199	The Association of HER-2/neu Amplification With Breast Cancer Recurrence. <i>Archives of Surgery</i> , 2000, 135, 1469.	2.3	48
200	Constitutive Tyrosine Phosphorylation of ErbB-2 via Jak2 by Autocrine Secretion of Prolactin in Human Breast Cancer. <i>Journal of Biological Chemistry</i> , 2000, 275, 33937-33944.	1.6	78
201	Importance of estrogen receptors for the behavior of invasive micropapillary carcinoma of the breast. Review of 68 cases with follow-up of 54. <i>Pathology Research and Practice</i> , 2000, 196, 35-39.	1.0	83
202	Monoclonal antibody therapy for solid tumors. <i>Cancer Treatment Reviews</i> , 2000, 26, 269-286.	3.4	142
203	Herceptin®: increasing survival in metastatic breast cancer. <i>European Journal of Oncology Nursing</i> , 2000, 4, 24-29.	0.9	26
204	Immunoelectron microscopical identification of the c-erbB-2 oncoprotein in patients with laryngeal squamous cell carcinoma. <i>Acta Histochemica</i> , 2000, 102, 403-411.	0.9	8

#	ARTICLE	IF	CITATIONS
205	Signal Transduction Pathway Targets for Anticancer Drug Discovery. <i>Current Pharmaceutical Design</i> , 2000, 6, 361-378.	0.9	36
206	Anti-HER2 therapy: how to use Herceptin® in clinical practice. <i>European Journal of Oncology Nursing</i> , 2000, 4, 30-36.	0.9	2
207	Prognostic and predictive implications of HER2 status for breast cancer patients. <i>European Journal of Oncology Nursing</i> , 2000, 4, 10-17.	0.9	19
208	HER2/neu Peptide-Based Vaccines, with GM-CSF as an Adjuvant, in Patients with Advanced-Stage HER2/neu-Expressing Cancers. <i>Clinical Lung Cancer</i> , 2000, 2, 74-77.	1.1	3
209	Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression. <i>Human Pathology</i> , 2001, 32, 1344-1350.	1.1	11
210	Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2). <i>European Journal of Cancer</i> , 2001, 37, 11-17.	1.3	54
211	HER2: The Neu Prognostic Marker for Breast Cancer. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2001, 38, 167-182.	2.7	11
212	The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification.. <i>Endocrine-Related Cancer</i> , 2001, 8, 11-31.	1.6	558
213	Comparison of Methods of Measuring HER-2 in Metastatic Breast Cancer Patients Treated With High-Dose Chemotherapy. <i>Journal of Clinical Oncology</i> , 2001, 19, 1698-1706.	0.8	89
214	BAG-1: A Novel Biomarker Predicting Long-Term Survival in Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 992-1000.	0.8	89
215	c-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER +) breast cancer patients with poor prognosis. <i>Annals of Oncology</i> , 2001, 12, 525-533.	0.6	51
216	2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*. <i>Journal of Clinical Oncology</i> , 2001, 19, 1865-1878.	0.8	770
217	Axillary Dissection over the Years: Where To from Here?. <i>World Journal of Surgery</i> , 2001, 25, 761-766.	0.8	20
218	Biological and clinical significance of her2 overexpression in Breast Cancer. <i>Breast Cancer</i> , 2001, 8, 45-51.	1.3	47
219	Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. <i>Histopathology</i> , 2001, 38, 96-104.	1.6	138
220	Pathobiologic Findings in DCIS of the Breast: Morphologic Features, Angiogenesis, HER-2/neu and Hormone Receptors. <i>Experimental and Molecular Pathology</i> , 2001, 70, 303-316.	0.9	70
221	Immunohistochemical determination of her2 expression in breast cancer from core biopsy specimens: a reliable predictor of her2 status of the whole tumor. <i>Breast Cancer Research and Treatment</i> , 2001, 69, 13-19.	1.1	50
222	HER4 Mediates Ligand-Dependent Antiproliferative and Differentiation Responses in Human Breast Cancer Cells. <i>Molecular and Cellular Biology</i> , 2001, 21, 4265-4275.	1.1	165

#	ARTICLE	IF	CITATIONS
223	Statistical Considerations in Assessing Molecular Markers for Cancer Prognosis and Treatment Efficacy. , 2002, 184, 169-189.		1
224	Receptor tyrosine kinase signalling as a target for cancer intervention strategies.. Endocrine-Related Cancer, 2001, 8, 161-173.	1.6	319
225	Loss of ErbB2 Expression in Pulmonary Metastatic Lesions in Osteosarcoma. Oncology, 2001, 60, 361-366.	0.9	48
226	HER2 â€“ a discussion of testing approaches in the USA. Annals of Oncology, 2001, 12, S101-S107.	0.6	34
227	HER2 as a prognostic and predictive marker for breast cancer. Annals of Oncology, 2001, 12, S23-S28.	0.6	109
228	The 93rd Annual Meeting of the American Association for Cancer Research. Expert Opinion on Pharmacotherapy, 2002, 3, 629-632.	0.9	0
230	HER2/neuAmplification in Breast Cancer. American Journal of Clinical Pathology, 2002, 117, 916-921.	0.4	98
231	FISH Detection of HER2 Amplification in Breast Cancer. , 2002, 204, 353-368.		2
233	"Build Quality in"--HER2 Testing in the Real World. Journal of the National Cancer Institute, 2002, 94, 788-789.	3.0	11
234	Title is missing!. Applied Immunohistochemistry & Molecular Morphology, 2002, 10, 40-46.	2.0	15
235	Quantitation of erbB2 positivity for evaluation of high-risk patients. Annals of Medicine, 2002, 34, 544-553.	1.5	2
236	Occult Axillary Lymph Node Metastases in Breast Cancer Do Matter. American Journal of Surgical Pathology, 2002, 26, 1286-1295.	2.1	57
237	Comparison of HER-2/ neu Oncogene Amplification Detected by Fluorescence In Situ Hybridization in Lobular and Ductal Breast Cancer. Applied Immunohistochemistry and Molecular Morphology, 2002, 10, 40-46.	0.6	39
238	Applications of Advances in Molecular Biology and Genomics to Clinical Cancer Care. Cancer Nursing, 2002, 25, 110-122.	0.7	5
239	Differential Gene Expression Patterns in HER2/neu-Positive and -Negative Breast Cancer Cell Lines and Tissues. American Journal of Pathology, 2002, 161, 1171-1185.	1.9	97
240	Defining the galaxy of gene expression in breast cancer. Breast Cancer Research, 2002, 4, 141-4.	2.2	17
241	Genogenic immunohistochemistry: a new era in diagnostic immunohistochemistry. Current Diagnostic Pathology, 2002, 8, 193-200.	0.4	16
242	Receptor tyrosine kinases as targets for anticancer drugs. Trends in Molecular Medicine, 2002, 8, 17-23.	3.5	228

#	ARTICLE	IF	CITATIONS
243	HER2/neu in the management of invasive breast cancer. <i>Journal of the American College of Surgeons</i> , 2002, 194, 488-501.	0.2	39
244	ErbB2 expression is correlated with increased survival of patients with osteosarcoma. <i>Cancer</i> , 2002, 94, 1397-1404.	2.0	109
245	Trastuzumab-associated cardiotoxicity. <i>Cancer</i> , 2002, 95, 1592-1600.	2.0	316
246	Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer. <i>British Journal of Surgery</i> , 2002, 89, 262-271.	0.1	49
247	Molecular alterations in sporadic breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 44, 121-141.	2.0	31
248	HER-2 in breast cancer—methods of detection, clinical significance and future prospects for treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 43, 231-244.	2.0	28
249	HER-2/Neu Overexpression Does Not Predict Response to Neoadjuvant Chemotherapy or Prognosticate Survival in Patients with Locally Advanced Breast Cancer. <i>Medical Oncology</i> , 2002, 19, 15-24.	1.2	11
250	The HER2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy. <i>Oncologist</i> , 2003, 8, 307-325.	1.9	561
251	Survival of patients with metastatic breast carcinoma. <i>Cancer</i> , 2003, 97, 545-553.	2.0	237
252	ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2. <i>Cancer</i> , 2003, 98, 1123-1130.	2.0	45
253	Absence of HER2 overexpression in metastatic malignant melanoma. <i>Journal of Surgical Oncology</i> , 2003, 84, 82-88.	0.8	21
254	The haematopoietic specific signal transducer Vav1 is expressed in a subset of human neuroblastomas. <i>Journal of Pathology</i> , 2003, 199, 526-533.	2.1	64
255	Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. <i>Oncogene</i> , 2003, 22, 761-768.	2.6	122
256	Heregulin-1 regulates the estrogen receptor-1 gene expression and activity via the ErbB2/PI 3-K/Akt pathway. <i>Oncogene</i> , 2003, 22, 2073-2087.	2.6	41
257	Comparing Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization Methods to Determine the HER2/neu Status in Primary Breast Carcinoma using Tissue Microarray. <i>Modern Pathology</i> , 2003, 16, 937-943.	2.9	52
258	Primer on Medical Genomics Part VI: Genomics and Molecular Genetics in Clinical Practice. <i>Mayo Clinic Proceedings</i> , 2003, 78, 307-317.	1.4	24
259	Topoisomerase II-1 (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. <i>European Journal of Cancer</i> , 2003, 39, 631-634.	1.3	106
260	Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention. <i>Oncologist</i> , 2003, 8, 5-17.	1.9	96

#	ARTICLE	IF	CITATIONS
261	Algorithm for the Diagnosis of HER-2/ neu Status in Breast-Infiltrating Carcinomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 465-470.	0.6	8
262	Cancer from an Unknown Primary Site. American Journal of the Medical Sciences, 2003, 326, 35-46.	0.4	17
263	HER-2/neu Testing in Breast Cancer. Pathology Patterns Reviews, 2003, 120, S53-S71.	0.4	28
264	Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon \hat{A} . Gut, 2004, 53, 123-129.	6.1	42
265	HER-2 Testing in Breast Cancer Using Parallel Tissue-Based Methods. JAMA - Journal of the American Medical Association, 2004, 291, 1972.	3.8	381
266	Expression of c-erbB-2 and p53 in Breast Carcinoma Patients: Comparison with Traditional Prognostic Factors and Survival. Journal of International Medical Research, 2004, 32, 455-464.	0.4	5
267	HER-2 Gene Amplification Correlates with Higher Levels of Angiogenesis and Lower Levels of Hypoxia in Primary Breast Tumors. Clinical Cancer Research, 2004, 10, 4083-4088.	3.2	60
268	Herceptin and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/neu. Cancer Investigation, 2004, 22, 706-712.	0.6	176
269	Kinase inhibitors in cancer therapy. Veterinary and Comparative Oncology, 2004, 2, 177-193.	0.8	30
270	HER2 Amplification Ratios by Fluorescence In Situ Hybridization and Correlation with Immunohistochemistry in a Cohort of 6556 Breast Cancer Tissues. Clinical Breast Cancer, 2004, 5, 63-69.	1.1	573
271	Expression of Vascular Endothelial Growth Factor and HER2/neu in Stage II Colon Cancer and Correlation with Survival. Clinical Colorectal Cancer, 2004, 4, 262-267.	1.0	47
272	Targeted Therapy in Breast Cancer. Molecular and Cellular Proteomics, 2004, 3, 379-398.	2.5	263
273	HER-2/neu Expression as a Predictive Factor for Response to Anthracycline-Based Chemotherapy in a Mexican Population of Locally Advanced Breast Cancer Patients. Medical Oncology, 2005, 22, 023-028.	1.2	4
274	Invasive lobular carcinoma: to grade or not to grade. Modern Pathology, 2005, 18, 621-628.	2.9	50
275	Node negative breast cancer: The prognostic value of DNA ploidy for long-term survival. British Journal of Surgery, 2005, 78, 844-848.	0.1	12
276	Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocrine-Related Cancer, 2005, 12, S135-S144.	1.6	90
277	Prognostic factors for breast cancer and their use in the clinical setting. Expert Review of Anticancer Therapy, 2005, 5, 269-281.	1.1	8
278	Interferon- \hat{I} Promotes the Anti-Proliferative Effect of Gefitinib (ZD1839) on Human Colon Cancer Cell Lines. Oncology, 2005, 69, 224-238.	0.9	15

#	ARTICLE	IF	CITATIONS
279	Interferon-alpha promotes the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines. <i>Cancer Letters</i> , 2005, 225, 61-74.	3.2	13
280	Evaluating and Staging the Patient with Breast Cancer. , 2005, , 309-318.		2
281	HER2 Overexpression as a Predictive Marker in a Randomized Trial Comparing Adjuvant Cyclophosphamide/Methotrexate/5-Fluorouracil with Epirubicin in Patients with Stage I/II Breast Cancer: Long-Term Results. <i>Clinical Breast Cancer</i> , 2005, 6, 253-259.	1.1	20
282	Genetic Alterations in Prostate Cancer. <i>Clinical Prostate Cancer</i> , 2005, 3, 220-229.	2.1	1
283	Prognostic/Predictive Factors in Breast Cancer. <i>Clinics in Laboratory Medicine</i> , 2005, 25, 809-825.	0.7	42
285	Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 269-280.	4.3	858
286	Prognostic Factors in Node-Negative Male Breast Cancer. <i>Clinical Breast Cancer</i> , 2006, 7, 331-335.	1.1	23
287	Herceptin: mechanisms of action and resistance. <i>Cancer Letters</i> , 2006, 232, 123-138.	3.2	407
288	Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. <i>Human Pathology</i> , 2006, 37, 1217-1226.	1.1	284
289	Accurate Identification of HER2-Positive Patients Is Essential for Superior Outcomes With Trastuzumab Therapy. <i>Oncology Nursing Forum</i> , 2006, 33, 265-272.	0.5	9
290	Invasive breast cancer trials. <i>Breast Cancer Online: BCO</i> , 2006, 9, 1-10.	0.1	0
291	Immunohistochemistry. , 2006, , 203-217.		1
292	HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. <i>Histopathology</i> , 2006, 48, 702-707.	1.6	108
293	Clinical trials design and treatment tailoring: General principles applied to breast cancer research. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 59, 98-105.	2.0	12
294	HER-2/neu Expression in Primary Breast Cancer With Sentinel Lymph Node Metastasis. <i>Annals of Surgical Oncology</i> , 2006, 13, 205-213.	0.7	13
295	Immunogenic HER-2/neu peptides as tumor vaccines. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 85-95.	2.0	65
296	Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 554-558.	1.1	24
297	HER 2/neu protein expression in colorectal cancer. <i>BMC Cancer</i> , 2006, 6, 123.	1.1	97

#	ARTICLE	IF	CITATIONS
298	Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer: The M.D. Anderson Cancer Center Experience. <i>Journal of Clinical Oncology</i> , 2006, 24, 4107-4115.	0.8	336
299	Development and Assessment of Conventional and Targeted Drug Combinations for Use in the Treatment of Aggressive Breast Cancers. <i>Current Cancer Drug Targets</i> , 2006, 6, 455-489.	0.8	36
300	Targeted Therapy of Breast Cancer. <i>Current Pharmaceutical Design</i> , 2007, 13, 497-517.	0.9	26
301	Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 1198-1207.	3.2	235
302	The Significance of c-erbB-2 Overexpression and p53 Expression in Patients With Axillary Lymph Node-Positive Breast Cancer: A Tissue Microarray Study. <i>International Journal of Surgical Pathology</i> , 2007, 15, 98-109.	0.4	9
304	HER-2/neu overexpression in invasive ductal breast cancer: An association with other prognostic and predictive factors. <i>Archive of Oncology</i> , 2007, 15, 15-18.	0.2	3
305	Targeting the Human Epidermal Growth Factor Receptor 2 (HER2) in the Treatment of Breast Cancer: Recent Advances and Future Directions. <i>Reviews on Recent Clinical Trials</i> , 2007, 2, 111-116.	0.4	46
306	PGDS, A Novel Technique Combining Chromogenic In Situ Hybridization and Immunohistochemistry for the Assessment of ErbB2 (HER2/neu) Status in Breast Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2007, 15, 316-324.	0.6	16
307	Managing High-Risk Breast Cancer. <i>Seminars in Oncology Nursing</i> , 2007, 23, 29-36.	0.7	1
308	HER2 status in early breast cancer: Relevance of cell staining patterns, gene amplification and polysomy 17. <i>European Journal of Cancer</i> , 2007, 43, 2339-2344.	1.3	54
309	Development of real-time quantitative reverse transcription-PCR for Her2 detection in peripheral blood from patients with breast cancer. <i>Clinica Chimica Acta</i> , 2007, 384, 52-56.	0.5	9
310	The 17q12-q21 amplicon: Her2 and topoisomerase-III α and their importance to the biology of solid tumours. <i>Cancer Treatment Reviews</i> , 2007, 33, 64-77.	3.4	69
311	Capecitabine and Trastuzumab in Heavily Pretreated Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 3853-3858.	0.8	144
312	HER-2-Positive Breast Cancer. <i>BioDrugs</i> , 2007, 21, 69-77.	2.2	30
313	American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5287-5312.	0.8	1,998
314	HER2-Positive Advanced Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 293-302.	0.9	6
315	Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. <i>Journal of Translational Medicine</i> , 2007, 5, 42.	1.8	42
317	Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. <i>Cancer</i> , 2007, 110, 489-498.	2.0	101

#	ARTICLE	IF	CITATIONS
318	Quality Indicators for the Care of Breast Cancer in Vulnerable Elders. <i>Journal of the American Geriatrics Society</i> , 2007, 55, S258-69.	1.3	5
319	Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. <i>Journal of Neuro-Oncology</i> , 2007, 85, 311-317.	1.4	127
320	Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007, 102, 375-381.	1.1	29
321	HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 423-429.	1.2	20
322	Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 903-910.	1.1	42
323	The significance of CXCR4 expression for the prediction of lymph node metastasis in breast cancer patients. <i>Chinese Journal of Clinical Oncology</i> , 2008, 5, 83-86.	0.0	2
325	Current issues in ER and HER2 testing by IHC in breast cancer. <i>Modern Pathology</i> , 2008, 21, S8-S15.	2.9	311
326	HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. <i>Oncogene</i> , 2008, 27, 6120-6130.	2.6	514
327	Molecular-targeted therapies: Lessons from years of clinical development. <i>Cancer Treatment Reviews</i> , 2008, 34, 61-80.	3.4	45
328	Targeted therapies in breast cancer. <i>Seminars in Diagnostic Pathology</i> , 2008, 25, 245-261.	1.0	39
329	Lower Level of MAPK Expression Is Associated with Anthracycline Resistance and Decreased Survival in Patients with Hormone Receptor Negative Breast Cancer. <i>Cancer Investigation</i> , 2008, 26, 671-679.	0.6	14
331	Identification of a Novel Immunogenic HLA-A*0201-Binding Epitope of HER-2/neu with Potent Antitumor Properties. <i>Journal of Immunology</i> , 2008, 181, 146-154.	0.4	30
332	Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers. <i>Journal of Clinical Oncology</i> , 2008, 26, 5697-5704.	0.8	260
333	Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting. <i>Journal of Clinical Oncology</i> , 2008, 26, 983-994.	0.8	287
334	Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer. <i>Oncology Reports</i> , 0, , .	1.2	3
335	Trastuzumab and Vinorelbine as Highly Effective and Safe Therapy for HER-2-Overexpressing Metastatic Breast Cancer. A Single Institution Experience. <i>Tumori</i> , 2008, 94, 464-468.	0.6	5
337	Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Central Nervous System Metastases. <i>Journal of Clinical Oncology</i> , 2009, 27, 5278-5286.	0.8	208
338	Molecular Subtypes of Breast Cancer Emerging in Young Women in Taiwan: Evidence for More Than Just Westernization as a Reason for the Disease in Asia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1807-1814.	1.1	103

#	ARTICLE	IF	CITATIONS
339	Trastuzumab. <i>Cancer Treatment and Research</i> , 2009, 151, 181-196.	0.2	5
340	Immunological Approaches in the Treatment of Metastasized Breast Cancer. <i>Breast Care</i> , 2009, 4, 359-366.	0.8	10
341	Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast Cancer. <i>American Journal of Surgical Pathology</i> , 2009, 33, 759-767.	2.1	85
342	Role of denosumab in breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 1225-1233.	1.4	7
343	Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer – A national survey performed at pathology departments in Sweden. <i>Acta Oncologica</i> , 2009, 48, 860-866.	0.8	22
344	Neuroblastoma-derived secretory protein is a novel secreted factor overexpressed in neuroblastoma. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2478-2489.	1.9	12
345	Chromogenic In Situ Hybridization Is a Reliable Method for Detecting HER2 Gene Status in Breast Cancer. <i>American Journal of Clinical Pathology</i> , 2009, 131, 490-497.	0.4	29
346	Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes. <i>Clinical Cancer Research</i> , 2009, 15, 7381-7388.	3.2	281
347	Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer. <i>BMC Cancer</i> , 2009, 9, 367.	1.1	22
348	Automated Quantitative Assessment of HER-2/neu Immunohistochemical Expression in Breast Cancer. <i>IEEE Transactions on Medical Imaging</i> , 2009, 28, 916-925.	5.4	95
349	Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 181-187.	1.1	76
350	MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 113-124.	1.1	93
351	Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. <i>British Journal of Cancer</i> , 2009, 100, 680-683.	2.9	93
352	Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. <i>British Journal of Cancer</i> , 2009, 100, 894-900.	2.9	159
353	Human epidermal growth factor receptor 2 oncoprotein expression in breast cancer patients from central Anatolia, Turkey. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2009, 5, 206-211.	0.7	0
354	The Economic Value of Innovative Treatments over the Product Life Cycle: The Case of Targeted Trastuzumab Therapy for Breast Cancer. <i>Value in Health</i> , 2009, 12, 1118-1123.	0.1	47
355	Protein kinases C isozymes are differentially expressed in human breast carcinomas. <i>Life Sciences</i> , 2009, 84, 766-771.	2.0	13
356	Current molecular diagnostics of breast cancer and the potential incorporation of microRNA. <i>Expert Review of Molecular Diagnostics</i> , 2009, 9, 455-466.	1.5	52

#	ARTICLE	IF	CITATIONS
357	Genomic Predictors of Outcome and Treatment Response in Breast Cancer. <i>Molecular Diagnosis and Therapy</i> , 2009, 13, 73-90.	1.6	35
359	PM1 PERSONALIZED MEDICINE: FACTORS INFLUENCING REIMBURSEMENT. <i>Value in Health</i> , 2009, 12, A3.	0.1	0
360	The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine. <i>Oncologist</i> , 2009, 14, 320-368.	1.9	986
361	Recent advances in multivalent self adjuvanting glycolipopeptide vaccine strategies against breast cancer. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2009, 57, 409-423.	1.0	13
362	Is it prime time for personalized medicine in cancer treatment?. <i>Personalized Medicine</i> , 2010, 7, 387-397.	0.8	1
363	Anticancer therapy induced cardiotoxicity: review of the literature. <i>Anti-Cancer Drugs</i> , 2010, 21, 578-590.	0.7	77
364	Trastuzumab-Based Therapy for Patients With HER2-Positive Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 186-195.	0.6	64
365	c-erbB-2 and the triple-state in early breast carcinomas. <i>Medical Oncology</i> , 2010, 27, 578-584.	1.2	5
366	Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 177-187.	1.1	46
367	Mechanisms of resistance to HER family targeting antibodies. <i>Experimental Cell Research</i> , 2010, 316, 1083-1100.	1.2	136
368	Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. <i>Cancer</i> , 2010, 116, 2856-2867.	2.0	95
369	Synergism from combined immunologic and pharmacologic inhibition of HER2 <i>in vivo</i> . <i>International Journal of Cancer</i> , 2010, 126, 2893-2903.	2.3	17
370	Estrogen/Progesterone Receptor Negativity and HER2 Positivity Predict Locoregional Recurrence in Patients With T1a,bN0 Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1296-1302.	0.4	79
371	Evaluation of HER-2 Overexpression of Breast Cancer at a Teaching Hospital in Saudi Arabia. <i>Breast Journal</i> , 2010, 16, 211-212.	0.4	0
372	BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. <i>British Journal of Cancer</i> , 2010, 103, 668-675.	2.9	259
373	Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance. <i>Clinical Medicine Insights: Oncology</i> , 2010, 4, CMO.S4773.	0.6	109
374	Metaplastic Breast Carcinoma: Clinicopathologic Features and Prognostic Value of Triple Negativity. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 112-118.	0.6	41
375	Does HER2 status influence locoregional failure rates in breast cancer patients treated with mastectomy for pT1-2pN0 disease?. <i>Annals of Oncology</i> , 2010, 21, 988-993.	0.6	9

#	ARTICLE	IF	CITATIONS
376	Adjuvant Trastuzumab for HER2-Positive Early Breast Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2010, 14, 326-336.	0.3	2
377	Biomarker Research in Breast Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2010, 14, 771-783.	0.3	4
378	Current therapies and novel targets in treatment of breast cancer. <i>Systematic Reviews in Pharmacy (discontinued)</i> , 2010, 1, 40.	0.6	5
379	Alteration of REDD1-Mediated Mammalian Target of Rapamycin Pathway and Hypoxia-Inducible Factor-1 α Regulation in Human Breast Cancer. <i>Pathobiology</i> , 2010, 77, 289-300.	1.9	14
380	An Adenoviral Vaccine Encoding Full-Length Inactivated Human Her2 Exhibits Potent Immunogenicity and Enhanced Therapeutic Efficacy without Oncogenicity. <i>Clinical Cancer Research</i> , 2010, 16, 1466-1477.	3.2	24
381	High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. <i>Breast Cancer Research</i> , 2010, 12, R25.	2.2	123
382	Expression of androgen receptors in primary breast cancer. <i>Annals of Oncology</i> , 2010, 21, 488-492.	0.6	288
383	Personalized medicine: Factors influencing reimbursement. <i>Health Policy</i> , 2010, 94, 91-100.	1.4	106
384	Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers. <i>Breast Cancer Research</i> , 2010, 12, R20.	2.2	42
386	Proteomics and biomarkers in clinical trials for drug development. <i>Journal of Proteomics</i> , 2011, 74, 2632-2641.	1.2	72
387	Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4491-4497.	0.8	228
388	Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls. <i>Lancet Oncology</i> , The, 2011, 12, 286-295.	5.1	66
389	A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies. <i>Breast Cancer Research</i> , 2011, 13, R117.	2.2	30
390	Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer. <i>Breast Cancer Research</i> , 2011, 13, R129.	2.2	25
391	Prognostic value of expression of intracellular and extracellular domains of HER2 in patients with HER2-positive breast cancer. <i>Wspolczesna Onkologia</i> , 2011, 5, 267-273.	0.7	2
392	Trastuzumab-Resistance and Breast Cancer. , 2011, , .		3
393	Testing for HER2 in Breast Cancer: A Continuing Evolution. <i>Pathology Research International</i> , 2011, 2011, 1-16.	1.4	41
394	Neuregulin1 as Novel Therapy for Heart Failure. <i>Current Pharmaceutical Design</i> , 2011, 17, 1808-1817.	0.9	20

#	ARTICLE	IF	CITATIONS
395	An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice. <i>Cancer Gene Therapy</i> , 2011, 18, 326-335.	2.2	22
396	Management and Outcome of HER2-Positive Early Breast Cancer Treated With or Without Trastuzumab in the Adjuvant Trastuzumab Era. <i>Clinical Breast Cancer</i> , 2011, 11, 93-102.	1.1	14
397	Targeting trastuzumab-resistant breast cancer cells with a lentivirus engineered to bind antibodies that recognize HER-2. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 89-97.	1.1	6
398	Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 407-420.	1.1	27
399	Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. <i>Immunologic Research</i> , 2011, 49, 235-247.	1.3	11
400	Significance of epidermal growth factor receptor expression in breast cancer. <i>Medical Oncology</i> , 2011, 28, 121-128.	1.2	51
401	Combination Treatment with HER-2 and VEGF Peptide Mimics Induces Potent Anti-tumor and Anti-angiogenic Responses in Vitro and in Vivo. <i>Journal of Biological Chemistry</i> , 2011, 286, 13626-13637.	1.6	45
402	Prognostic Implications of MicroRNA-21 Overexpression in Invasive Ductal Carcinomas of the Breast. <i>Journal of Breast Cancer</i> , 2011, 14, 269.	0.8	69
403	Comparative profiling of plasma proteome from breast cancer patients reveals thrombospondin-1 and BRWD3 as serological biomarkers. <i>Experimental and Molecular Medicine</i> , 2012, 44, 36.	3.2	45
404	Lymph Node Ratio. <i>International Journal of Surgical Pathology</i> , 2012, 20, 546-554.	0.4	7
405	The Effect of Cold Ischemia Time and/or Formalin Fixation on Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Results in Breast Carcinoma. <i>Pathology Research International</i> , 2012, 2012, 1-7.	1.4	27
406	Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. <i>Annals of Oncology</i> , 2012, 23, 897-902.	0.6	135
407	Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 2145-2151.	1.2	10
408	Peptide vaccines and peptidomimetics targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. <i>Future Oncology</i> , 2012, 8, 961-987.	1.1	44
409	Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma. <i>Pharmacological Research</i> , 2012, 65, 23-30.	3.1	40
410	Role of HER2-neu as a prognostic factor for survival and relapse in pT1aâ€“bNOMO breast cancer: a systematic review of the literature with a pooled-analysis. <i>Medical Oncology</i> , 2012, 29, 2586-2593.	1.2	35
411	Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series. <i>Journal of Oncology</i> , 2012, 2012, 1-6.	0.6	4
412	Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. <i>Molecular Immunology</i> , 2012, 50, 200-209.	1.0	88

#	ARTICLE	IF	CITATIONS
413	Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition. <i>Journal of Translational Medicine</i> , 2012, 10, 28.	1.8	77
414	Accurate Sensitivity of Quantum Dots for Detection of HER2 Expression in Breast Cancer Cells and Tissues. <i>Journal of Fluorescence</i> , 2013, 23, 293-302.	1.3	12
415	Serum HER-2: sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1005-1013.	1.2	15
416	CDC25A Protein Stability Represents a Previously Unrecognized Target of HER2 Signaling in Human Breast Cancer: Implication for a Potential Clinical Relevance in Trastuzumab Treatment. <i>Neoplasia</i> , 2013, 15, 579-590.	2.3	18
418	Kinase dysfunction and kinase inhibitors. <i>Veterinary Dermatology</i> , 2013, 24, 181.	0.4	17
419	Molecular/Targeted Therapy of Cancer. , 2013, , 215-244.		0
420	Metabolism-Related Proteins Are Differentially Expressed according to the Molecular Subtype of Invasive Breast Cancer Defined by Surrogate Immunohistochemistry. <i>Pathobiology</i> , 2013, 80, 41-52.	1.9	82
421	Molecular and clinicopathological markers of prognosis in breast cancer. <i>Expert Review of Molecular Diagnostics</i> , 2013, 13, 481-498.	1.5	4
422	Evaluation of Biomarkers in Multifocal/Multicentric Invasive Breast Carcinomas. <i>International Journal of Surgical Pathology</i> , 2013, 21, 126-132.	0.4	11
423	Trastuzumab-Related Cardiotoxicity in Early Breast Cancer: A Cohort Study. <i>Oncologist</i> , 2013, 18, 795-801.	1.9	43
424	Clinical Significance of Lymph Node Ratio in Locally Advanced Breast Cancer Molecular Subtypes. <i>Onkologie</i> , 2013, 36, 4-4.	1.1	1
425	Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status. <i>Cancer</i> , 2013, 119, 3113-3122.	2.0	30
426	Antitumor Activity of a Monoclonal Antibody Targeting Major Histocompatibility Complex Class II Her2 Peptide Complexes. <i>Journal of the National Cancer Institute</i> , 2013, 105, 202-218.	3.0	25
428	Serial Changes in Expression of Proteins in Response to Neoadjuvant Chemotherapy in Breast Cancer. , 2013, , .		2
429	Significance of immunohistochemistry in breast cancer. <i>World Journal of Clinical Oncology</i> , 2014, 5, 382.	0.9	172
430	ERBB2 Increases Metastatic Potentials Specifically in Androgen-Insensitive Prostate Cancer Cells. <i>PLoS ONE</i> , 2014, 9, e99525.	1.1	19
431	Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer - results from the HER-OS patient registry. <i>BMC Cancer</i> , 2014, 14, 806.	1.1	30
432	Morphologic and molecular subtype status of individual tumor foci in multiple breast carcinoma. A study of 155 cases with analysis of 463 tumor foci. <i>Human Pathology</i> , 2014, 45, 409-416.	1.1	13

#	ARTICLE	IF	CITATIONS
433	Acute Cardiotoxic Effects of Adjuvant Trastuzumab Treatment and Its Relation to Oxidative Stress. <i>Angiology</i> , 2014, 65, 944-949.	0.8	19
434	Comparison of <sc>HER</sc>2 expression between primary colorectal cancer and their corresponding metastases. <i>Cancer Medicine</i> , 2014, 3, 674-680.	1.3	42
435	Molecular Testing in Cancer. , 2014, , .		2
436	Time to Initiation of Adjuvant Chemotherapy for Early Breast Cancer and Outcome: The Earlier, the Better?. <i>Journal of Clinical Oncology</i> , 2014, 32, 717-719.	0.8	15
437	Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 735-744.	0.8	237
438	Long term survival of HER2-positive early breast cancer treated withÂtrastuzumab-based adjuvant regimen: A large cohort study fromÂclinical practice. <i>Breast</i> , 2014, 23, 573-578.	0.9	19
439	Highly Sensitive Single Domain Antibodyâ€“Quantum Dot Conjugates for Detection of HER2 Biomarker in Lung and Breast Cancer Cells. <i>ACS Nano</i> , 2014, 8, 5682-5695.	7.3	89
440	Early Biomarkers in Breast Cancer. , 2014, , 569-638.		0
442	NatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancer. <i>Systematic Reviews</i> , 2015, 4, 133.	2.5	2
444	Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 151-161.	1.1	47
445	Feasibility and Cardiac Safety of Trastuzumab Emtansine After Anthracycline-Based Chemotherapy As (neo)Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2â€“Positive Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1136-1142.	0.8	67
446	A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1368-1386.	1.4	16
447	Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 357-364.	1.1	22
448	The Ad5 [E1-, E2b]-based vector: a new and versatile gene delivery platform. , 2015, , .		0
449	Targeting epidermal growth factor receptors and downstream signaling pathways in cancer by phytochemicals. <i>Targeted Oncology</i> , 2015, 10, 337-353.	1.7	19
450	Long-Term Follow-Up After Preoperative Trastuzumab and Chemotherapy for HER2-Overexpressing Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 24-30.	1.1	14
451	Wip1 phosphatase in breast cancer. <i>Oncogene</i> , 2015, 34, 4429-4438.	2.6	40
452	The role of surgeons in building a personalized medicine program. <i>Journal of Surgical Oncology</i> , 2015, 111, 3-8.	0.8	5

#	ARTICLE	IF	CITATIONS
453	Current therapeutic strategies of anti-HER2 treatment in advanced breast cancer patients. <i>Wspolczesna Onkologia</i> , 2016, 1, 1-7.	0.7	3
454	Structural identification of an HER2 receptor model binding pocket to optimize lead compounds: a combined experimental and computational approach. <i>Molecular BioSystems</i> , 2016, 12, 2159-2167.	2.9	8
455	The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 361-370.	1.1	11
456	Molecular biotechnology for diagnostics. , 2016, , 303-343.		3
457	Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems. <i>BMC Cancer</i> , 2016, 16, 200.	1.1	14
458	A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 521-530.	1.1	27
459	Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology. <i>Annals of Surgical Oncology</i> , 2017, 24, 3502-3509.	0.7	44
460	Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System. <i>Oncologist</i> , 2017, 22, 1292-1300.	1.9	84
461	Preparation and preclinical evaluation of ^{131}I -trastuzumab for breast cancer. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2017, 60, 12-19.	0.5	13
462	Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe. <i>Scientific Reports</i> , 2018, 8, 2998.	1.6	22
463	Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer. <i>Oncogene</i> , 2018, 37, 2502-2514.	2.6	69
464	Locally Advanced Breast Cancer. , 2018, , 819-831.e6.		3
465	Chemotherapy and HER2-Directed Therapy for Metastatic Breast Cancer. , 2018, , 885-906.e8.		2
466	Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches. <i>Bioconjugate Chemistry</i> , 2018, 29, 3937-3966.	1.8	23
467	Single molecule localization microscopy coupled with touch preparation for the quantification of trastuzumab-bound HER2. <i>Scientific Reports</i> , 2018, 8, 15154.	1.6	28
468	A combination of p53-activating APR-246 and phosphatidylerine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts. <i>Breast Cancer: Targets and Therapy</i> , 2018, Volume 10, 53-67.	1.0	8
469	Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-21.	0.7	60
470	HER2-Based Immunotherapy for Breast Cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2018, 33, 169-175.	0.7	10

#	ARTICLE	IF	CITATIONS
471	Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients. <i>Scientific Reports</i> , 2019, 9, 16894.	1.6	8
472	A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancer. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	23
473	Targeted Therapies in Veterinary Oncology. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 2019, 49, 917-931.	0.5	12
474	Analysis of hormone receptor status in primary and recurrent breast cancer via data mining pathology reports. <i>Open Medicine (Poland)</i> , 2019, 14, 91-98.	0.6	9
475	Prognostic models for breast cancer: a systematic review. <i>BMC Cancer</i> , 2019, 19, 230.	1.1	107
476	An Integrating Analysis Reveals Key Regulatory Networks in Breast Cancer. , 2019, , .		0
477	Molecular/Targeted Therapy of Cancer. , 2019, , 251-285.		0
478	Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. <i>Clinical Cancer Research</i> , 2019, 25, 2725-2736.	3.2	50
479	SPR and NMR characterization of the molecular interaction between A9 peptide and a model system of HER2 receptor: A fragment approach for selecting peptide structures specific for their target. <i>Journal of Peptide Science</i> , 2020, 26, e3231.	0.8	4
480	Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer. <i>Cardio-Oncology</i> , 2020, 6, 26.	0.8	8
481	Peptide Ligands Specifically Targeting HER2 Receptor and the Role Played by a Synthetic Model System of the Receptor Extracellular Domain: Hypothesized Future Perspectives. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 15333-15343.	2.9	7
482	Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis. <i>Oncogene</i> , 2020, 39, 6589-6605.	2.6	50
483	Validation of CTS5 model in large-scale breast cancer population and the impact of menopausal and HER2 status on its prognostic value. <i>Scientific Reports</i> , 2020, 10, 4660.	1.6	10
484	Targeted immunotherapy for HER2-low breast cancer with 17p loss. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	14
485	Relative Risk of Peripheral Neuropathy With Ado-Trastuzumab Emtansine (T-DM1) Compared to Taxane-Based Regimens in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Cancers: A Systematic Review and Meta-Analysis. <i>Cureus</i> , 2021, 13, e15282.	0.2	4
486	Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase. <i>Cancer Treatment and Research</i> , 1994, 71, 161-191.	0.2	22
487	Breast Cancer: Influence of Endocrine Hormones, Growth Factors and Genetic Alterations. <i>Advances in Experimental Medicine and Biology</i> , 1993, 330, 119-141.	0.8	16
488	Activated oncogenes and putative tumor suppressor genes involved in human breast cancers. <i>Cancer Treatment and Research</i> , 1993, 63, 15-60.	0.2	38

#	ARTICLE	IF	CITATIONS
489	Defining the high-risk breast cancer patient. <i>Cancer Treatment and Research</i> , 1992, 60, 161-187.	0.2	2
490	Prognostic factors in axillary node-negative breast cancer. <i>Cancer Treatment and Research</i> , 1991, 61, 3-19.	0.2	1
491	Anti-p185HER2 monoclonal antibodies: Biological properties and potential for immunotherapy. <i>Cancer Treatment and Research</i> , 1991, 61, 193-211.	0.2	29
492	Tyrosine kinase receptor " nuclear protooncogene interactions in breast cancer. <i>Cancer Treatment and Research</i> , 1991, 61, 249-273.	0.2	19
493	c-erb B2 amplification and overexpression in human tumors. <i>Cancer Treatment and Research</i> , 1991, , 161-179.	0.2	33
494	Clinical significance of erbB2 protein overexpression. <i>Cancer Treatment and Research</i> , 1991, 61, 181-191.	0.2	11
495	Oncogenes as clinical prognostic indicators. <i>Cancer Treatment and Research</i> , 1991, 53, 3-22.	0.2	8
496	Mammary tumor fibroblasts are phenotypically distinct from non-tumor fibroblasts. <i>Exs</i> , 1995, 74, 249-271.	1.4	7
497	Oncogenes and Growth Factor Receptors As Diagnostic and Prognostic Markers in Precancers and Cancers of the Oral Mucosa. <i>Current Topics in Pathology Ergebnisse Der Pathologie</i> , 1996, 90, 223-239.	0.2	6
498	Adjuvant and Neoadjuvant Chemotherapy in Gastric Cancer: A Review. , 1993, , 404-414.		2
499	Central Nervous System Tumours in Women Who Received Capecitabine and Lapatinib Therapy for Metastatic Breast Cancer. , 2011, , 97-106.		8
500	HER-2/neu Oncogene Amplification and Expression in Human Mammary Carcinoma. , 1991, , 75-97.		6
501	EGF Family Receptors and Their Ligands in Human Cancer. , 1998, , 113-165.		13
502	The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. <i>Journal of Biological Chemistry</i> , 1991, 266, 1716-1720.	1.6	174
503	p185HER2 signal transduction in breast cancer cells. <i>Journal of Biological Chemistry</i> , 1991, 266, 14300-14305.	1.6	81
504	Purification and characterization of the neu/erb B2 ligand-growth factor from bovine kidney.. <i>Journal of Biological Chemistry</i> , 1992, 267, 11508-11512.	1.6	37
506	Real-Time PCR Technology for Cancer Diagnostics. <i>Clinical Chemistry</i> , 2002, 48, 1178-1185.	1.5	218
507	Plasma Membrane Phosphotyrosine, Her2-NEU, and Epidermal Growth Factor Receptor in Human Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1996, 19, 552-557.	0.6	8

#	ARTICLE	IF	CITATIONS
508	Her-2/ neu and Breast Cancer. Diagnostic Molecular Pathology, 2001, 10, 139-152.	2.1	173
509	Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget, 2015, 6, 20099-20110.	0.8	41
510	Dual inhibition of ErbB1 and ErbB2 in cancer by recombinant human prolidase mutant hPEPD-G278D. Oncotarget, 0, 7, 42340-42352.	0.8	18
511	Cheminformatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors. Current Topics in Medicinal Chemistry, 2016, 16, 1452-1462.	1.0	4
512	Small Molecule Inhibitors of the Prolactin Receptor in Breast Cancer. The Open Conference Proceedings Journal, 2010, 1, 39-45.	0.6	3
513	Mechanisms of Trastuzumab Resistance and Opportunities to Overcome Therapeutic Resistance. Journal of Molecular Biomarkers & Diagnosis, 2013, 04, .	0.4	1
514	Prognostic Factors in Breast Cancer. Archives of Pathology and Laboratory Medicine, 2000, 124, 966-978.	1.2	916
515	Trastuzumab as Adjuvant Therapy for Early Breast Cancer: The Importance of Accurate Human Epidermal Growth Factor Receptor 2 Testing. Archives of Pathology and Laboratory Medicine, 2008, 132, 1008-1015.	1.2	49
516	HER2 Testing in Breast Cancer: NCCN Task Force Report and Recommendations. Journal of the National Comprehensive Cancer Network: JNCCN, 2006, 4, S-1-S-22.	2.3	75
517	A careful reassessment of anthracycline use in curable breast cancer. Npj Breast Cancer, 2021, 7, 134.	2.3	25
519	Correlation of Serum c-erbB-2 Protein Level with the Prognosis in Patients with Primary Breast Cancer.. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2001, 62, 8-16.	0.0	0
520	HER2 and Topoisomerase II α in Breast Carcinoma. , 2004, , 261-283.		0
521	Biology of Breast Cancer. , 2006, , 39-70.		0
522	Is There a Role for ErbB Dual Kinase Inhibition?. Translational Medicine Series, 2007, , 203-212.	0.0	0
523	Correlation of HER2 protein expression and HER2 gene amplification with cellular atypism in fine needle aspirates of invasive breast cancer. The Journal of the Japanese Society of Clinical Cytology, 2007, 46, 197-202.	0.0	0
524	Cytopathology of the Breast. , 2009, , 675-695.		0
525	Metaplastic breast carcinoma: clinicopathologic features and prognostic value of triple-negativity.. , 2009, , .		1
526	Chemotherapy for Metastatic Breast Cancer. , 2009, , 1233-1261.		2

#	ARTICLE	IF	CITATIONS
527	Locally Advanced Breast Cancer. , 2009, , 1189-1199.		0
528	Premalignant and Malignant Breast Pathology. , 2010, , 169-179.		0
529	Trastuzumab as Adjuvant Treatment for Early Stage HER-2-positive Breast Cancer. , 2011, , 33-49.		0
530	Prognostic Markers in Breast Cancer. , 2013, , 25-42.		0
531	Histopathology and Grading of Breast Cancer. , 2013, , 1-27.		2
533	Molecular Testing in Breast Cancer. , 2014, , 169-188.		0
534	Expression and Prognostic Significance of the HER-2/neu Oncogene During the Evolutionary Progression of Human Breast Cancer. , 1991, , 69-82.		1
535	Growth Factors as Local Regulators of Normal and Malignant Human Mammary Epithelium. , 1991, , 129-148.		1
536	PROGNOSTIC FACTORS IN OPERABLE BREAST CANCER. The Journal of the Japanese Practical Surgeon Society, 1992, 53, 1052-1058.	0.0	0
537	Establishing a Clinical Molecular Biology Laboratory. , 1993, , 1-38.		0
538	Chemotherapy for Node-Negative Breast Cancer. Medical Radiology, 1993, , 43-56.	0.0	1
539	Biological Factors and Treatment Decision in Early Breast Cancer. , 1993, , 327-334.		0
540	Estrogen and Anti-Estrogen Regulation of Amplified erbB2 Gene Expression in Human Breast Cancer Cells. , 1996, , 418-423.		0
541	HER-2/neu as a predictive marker of response to breast cancer therapy. , 1998, , 155-167.		0
542	HER-2/neu in Breast Cancer: A Possible Means of Therapy?. , 1998, , 121-136.		0
543	Early Biomarkers in Breast Cancer. , 2015, , 61-142.		0
544	Factors contributing to suboptimal tumour preservation in breast carcinoma specimens at a tertiary health care setting in Sri Lanka. The Sri Lanka Journal of Surgery, 2016, 34, 1.	0.0	0
545	Peptide-Based Cancer Vaccines and Therapeutics for Solid Tumors Overexpressing HER-1, HER-2, HER-3, VEGF and IGF-1R. , 2017, , 1-31.		0

#	ARTICLE	IF	CITATIONS
546	A case of cerebral embolism induced by serious cardiac failure after repeated administration of trastuzumab and epirubicin. <i>Nosotchu</i> , 2018, 40, 200-204.	0.0	0
547	Role of Heat Shock Protein 90 in Mammary Tumorigenesis. <i>Heat Shock Proteins</i> , 2019, , 103-124.	0.2	0
548	Clinical Trials in the Era of Treatment Tailoring. , 2006, , 1007-1020.		0
549	Clinical decision-making in early breast cancer. <i>Annals of Surgery</i> , 1993, 217, 207-25.	2.1	72
550	Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. <i>American Journal of Pathology</i> , 1996, 148, 549-58.	1.9	67
551	The EGF receptor family—multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4. <i>Transactions of the American Clinical and Climatological Association</i> , 2003, 114, 315-33; discussion 333-4.	0.9	48
552	Trastuzumab in the management of early and advanced stage breast cancer. <i>Biologics: Targets and Therapy</i> , 2007, 1, 19-31.	3.0	33
555	A flow cytometric study of c-erbB-3 expression in breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 1995, 41, 280-286.	2.0	1
556	Multisite phosphotyping of the ErbB-2 oncoprotein in human breast cancer. <i>Molecular Diagnosis and Therapy</i> , 2001, 6, 17-25.	1.3	8
557	Overexpression of galectin2 (LGALS2) predicts a better prognosis in human breast cancer.. <i>American Journal of Translational Research (discontinued)</i> , 2022, 14, 2301-2316.	0.0	0
558	Synthesis and comparative evaluation of 177Lu-labeled PEG and non-PEG variant peptides as HER2-targeting probes. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
560	Her2 Expression in Thyroid Tumors. <i>American Surgeon</i> , 2003, 69, 1100-1103.	0.4	10
561	Using quantitative single molecule localization microscopy to optimize multivalent HER2-targeting ligands. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	0
562	Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy. <i>Antioxidants</i> , 2023, 12, 457.	2.2	3
563	Mecanismos de resistencia al trastuzumab. , 2023, 17, .		0
566	HER2-Sish Histopathology Image Classification Using Deep Neural Networks. , 2023, , .		0